ATHE
Q1 2027 EPS Estimate
$-0.03
Mar 4, 2027
Revenue Estimate
$800,757
FY2031E EPS$0.01

Analyst Sentiment

Wall St. Consensus
Buy
7 analysts·Limited coverage
64
Score
4 Buy (57%)3 Hold (43%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
457%
Hold
343%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$2.00
-48.1%
Consensus
$10.00
+159.7%
Bull
$12.00
+211.7%
12-Month Target Range7 analysts
$2.00$10.00$12.00
Current $3.85Consensus
Current Price
$3.85
Upside to Consensus
$6.15

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-41.05%
EPS
FY2028
Rev+116.53%
EPS
FY2029
Rev+76.99%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2027EFY2028EFY2029EFY2030EFY2031E
Revenue Avg$1M$3M$5M$14M$68M
Low$1M$3M$5M$14M$68M
High$1M$3M$5M$14M$68M
EBITDA Avg$-4M$-6M$-8M$-4M$345,728
Low$-4M$-6M$-8M$-4M$345,728
High$-4M$-6M$-8M$-4M$345,728
EBIT Avg$-5M$-6M$-8M$-4M$238,892
Low$-5M$-6M$-8M$-4M$238,892
High$-5M$-6M$-8M$-4M$238,892
Net Income Avg$-5M$-6M$-8M$-4M$188,725
Low$-5M$-6M$-8M$-4M$188,725
High$-5M$-6M$-8M$-4M$188,725
EPS Avg$-0.26$-0.34$-0.44$-0.24$0.01
Low$-0.26$-0.34$-0.44$-0.24$0.01
High$-0.26$-0.34$-0.44$-0.24$0.01
Analysts (Rev / EPS)5 / 26 / 23 / 13 / 14 / 1

Earnings Surprises

Recent Analyst Actions

Sep 15, 2026Lake Street
Alterity Therapeutics initiated with a Buy at Lake Street
Target:$10.00
+159.1%from $3.86
Aug 11, 2026UBS
Craig-Hallum bullish on Alterity Therapeutics, initiates with a Buy
Target:$12.00
+154.2%from $4.72
Aug 11, 2026Craig-Hallum
Craig-Hallum bullish on Alterity Therapeutics, initiates with a Buy
Target:$2.00
-57.6%from $4.72
Aug 11, 2026Craig-Hallum
Alterity Therapeutics initiated with a Buy at Craig-Hallum
Target:$12.00
+164.0%from $4.54
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.